ResMed Inc. $RMD Shares Acquired by Giverny Capital Inc.

Posted by Francis Steltz on Sep 7th, 2026

Giverny Capital Inc. boosted its holdings in ResMed Inc. (NYSE:RMD – Free Report) by 68.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 387,665 shares of the medical equipment provider’s stock after purchasing an additional 157,660 shares during the period. ResMed comprises 2.6% of Giverny Capital Inc.’s portfolio, making the stock its 18th largest position. Giverny Capital Inc.’s holdings in ResMed were worth $75,548,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Terra Nova Asset Management LLC increased its holdings in ResMed by 0.6% during the 3rd quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider’s stock worth $2,136,000 after purchasing an additional 46 shares during the last quarter. Kera Capital Partners Inc. boosted its stake in shares of ResMed by 6.6% during the 4th quarter. Kera Capital Partners Inc. now owns 841 shares of the medical equipment provider’s stock valued at $217,000 after buying an additional 52 shares during the last quarter. Andina Capital Management LLC boosted its stake in shares of ResMed by 2.9% during the 4th quarter. Andina Capital Management LLC now owns 1,988 shares of the medical equipment provider’s stock valued at $479,000 after buying an additional 56 shares during the last quarter. Turtle Creek Wealth Advisors LLC grew its position in shares of ResMed by 6.2% during the first quarter. Turtle Creek Wealth Advisors LLC now owns 994 shares of the medical equipment provider’s stock worth $223,000 after buying an additional 58 shares in the last quarter. Finally, Inspire Investing LLC grew its position in shares of ResMed by 7.9% during the fourth quarter. Inspire Investing LLC now owns 902 shares of the medical equipment provider’s stock worth $217,000 after buying an additional 66 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Trading Down 0.0%

NYSE:RMD opened at $228.25 on Monday. The firm has a market capitalization of $32.93 billion, a P/E ratio of 21.88, a P/E/G ratio of 1.44 and a beta of 0.77. The business has a 50 day simple moving average of $215.51 and a 200 day simple moving average of $217.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.10 and a quick ratio of 2.42. ResMed Inc. has a 12-month low of $180.26 and a 12-month high of $284.87.

ResMed (NYSE:RMD – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 EPS for the quarter, topping the consensus estimate of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. ResMed’s quarterly revenue was up 8.6% on a year-over-year basis. Equities research analysts predict that ResMed Inc. will post 12.02 EPS for the current year.

ResMed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Investors of record on Thursday, August 20th will be paid a dividend of $0.66 per share. This is an increase from ResMed’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. ResMed’s dividend payout ratio (DPR) is presently 25.31%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RMD. Royal Bank Of Canada lifted their price target on shares of ResMed from $234.00 to $244.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. Morgan Stanley reiterated an “equal weight” rating and set a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Rothschild & Co Redburn began coverage on shares of ResMed in a research report on Wednesday, August 19th. They issued a “neutral” rating and a $230.00 target price for the company. Weiss Ratings upgraded shares of ResMed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Finally, UBS Group restated a “buy” rating and issued a $300.00 target price on shares of ResMed in a research note on Tuesday, July 21st. Six research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $240.31.

Get Our Latest Research Report on ResMed

Insider Activity

In other ResMed news, Director Peter Farrell sold 970 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total transaction of $227,688.10. Following the transaction, the director owned 51,803 shares of the company’s stock, valued at approximately $12,159,718.19. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,991 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $205.69, for a total transaction of $1,026,598.79. Following the sale, the chief executive officer owned 466,256 shares in the company, valued at $95,904,196.64. This trade represents a 1.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,952 shares of company stock valued at $4,145,070 in the last ninety days. Corporate insiders own 0.65% of the company’s stock.

About ResMed

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.